Additional Information
Market: NASDAQ
Sector: Pharmaceuticals & Biotech
Latest Price: 1.54  (0.65% Ascending)
52-week High: 2.57
52-week Low: 0.95
Market Cap: 77.64M
1 year chart
1 day chart
Apricus Biosciences

Apricus Biosciences is a pharmaceutical research and development company focused on the design and development of products and technologies in multiple therapeutic areas, including oncology, sexual dysfunction, autoimmune diseases and pain/inflammation

Apricus Biosciences inks exclusive European collaboration for Vitaros with Novartis unit

15th Feb 2012, 3:38 pm by Brad Lemaire
Apricus Biosciences inks exclusive European collaboration for Vitaros with Novartis unit

Apricus Biosciences (NASDAQ:APRI) said Wednesday it has signed an exclusive collaboration to market Vitaros, an erectile dysfunction medication, with Novartis AG’s (NYSE:NVS) Sandoz division.

According to the deal, Sandoz will pay Apricus Biosciences up to 21 million euros, or $27.4 million. The payment will be divided into a fixed upfront payment and specific commercial milestones, as well as double-digit royalties on net sales.

"We are very excited about this major European collaboration with such an important international pharmaceutical company as Sandoz,” chief executive Bassam Damaj said in a statement.

"This is yet another important milestone in our strategy to make Vitaros available worldwide and the successful continuation of the execution of our commercialization strategy of Vitaros."

Apricus' drug Vitaros is approved in Canada and the specialty pharmaceutical company has also filed for marketing approval in the United States.

San Diego, California-based Apricus already licensed the Canadian marketing rights of Vitaros to Abbott Laboratories (NYSE:ABT) in January and the Italian marketing rights to Bracco SpA in 2010.

Apricus, founded in 1987 and with about 35 employees, makes drug candidates based on its NexACT delivery technology.

The NexACT technology is designed to enhance the delivery of an active drug to improve therapeutic outcomes and cut down systemic side effects associated with oral and injectable medications.

Shares of the company were up 4.68 percent at $3.58 each on the Nasdaq Wednesday afternoon.

No investment advice

Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here